Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory
Academic Radiology · 2025
DOI: 10.1016/j.acra.2025.05.013 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Academic Radiology, 2025. Verfasst von Yue Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Avenue., Guangzhou 510630, PR China (…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
RATIONALE AND OBJECTIVE: The treatment scheme in hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE) is still controversial. OBJECTIVE: To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with apatinib plus camrelizumab (TRIPLET protocol) versus HAIC alone for HCC refractory to TACE. MATERIALS AND METHODS: From April 2019 to September 2024, a total of 275 patients with intermediate-stage HCC refractory to TACE based on modified Response Evaluation Criteria in Solid Tumors criteria by two radiologists were reviewed, classifying into the HAIC group (n = 117) and TRIPLET group (n = 158). Propensity score matching (PSM) method was used to reduce the selective bias. The overall survival (OS) and post progression-free survival (PPS) were compared using the Kaplan-Meier method with log-rank test. Multivariable analyses of independent prognostic factors were evaluated by means of the forward stepwise Cox regression model. RESULTS: After PSM 1:1, the median OS was 11.5 months in TRIPLET group was longer significantly than that (median OS was 7.8 months) in HAIC group (P 5 cm (HR: 1.67; 95% CI: 1.34-2.09; P < 0.001) and HAIC treatment (HR: 1.67; 95% CI: 1.08-2.63; P = 0.025) significantly affected the PPS. CONCLUSION: This TRIPLET protocol has significant safety and effectiveness in the management of patients with HCC refractory to TACE. DESIGN: A retrospective, multi-institutional study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Avenue., Guangzhou 510630, PR China (Y.Z., C.L.).
- Department of Oncology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong 510180, PR China (Y.W.).
- Department of Gastroenterology, Wugang City People's Hospital, Shaoyang, Hunan 422400, China (K.L.).
- Department of Oncology, Wugang City People's Hospital, Shaoyang, Hunan 422400, China (B.Y., X.D., Y.C.).
- Department of Respiratory Medicine, Wugang City People's Hospital, Shaoyang, Hunan 422400, China (C.L.).
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Avenue., Guangzhou 510630, PR China (Y.Z., C.L.). Electronic address: lichengzhi@jnu.edu.cn.
Zitieren
APA
Zhao, Y., Wu, Y., Lin, K., Yang, B., Deng, X., Lu, C., Chen, Y., & Li, C. (2025). Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory. Academic Radiology. https://doi.org/10.1016/j.acra.2025.05.013
Vancouver
Zhao Y, Wu Y, Lin K, Yang B, Deng X, Lu C, et al. Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory. Academic Radiology. 2025. doi:10.1016/j.acra.2025.05.013
BibTeX
@article{Zhao2025,
author = {Zhao, Yue and Wu, Yong and Lin, Kai and Yang, Bin and Deng, Xiaojuan and Lu, Chunlin and Chen, Yifang and Li, Chengzhi},
title = {Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory},
journal = {Academic Radiology},
year = {2025},
doi = {10.1016/j.acra.2025.05.013}
}
EUVIMED